|1.||Rowe, Christopher C: 7 articles (10/2015 - 04/2007)|
|2.||Villemagne, Victor L: 7 articles (10/2015 - 04/2007)|
|3.||Rinne, J O: 7 articles (02/2014 - 11/2006)|
|4.||Mathis, Chester A: 6 articles (01/2015 - 01/2008)|
|5.||Någren, K: 6 articles (02/2014 - 11/2006)|
|6.||Brooks, David J: 5 articles (11/2013 - 07/2006)|
|7.||Masters, Colin L: 5 articles (06/2013 - 04/2007)|
|8.||Aalto, S: 5 articles (03/2011 - 11/2006)|
|9.||Viitanen, M: 5 articles (03/2011 - 11/2006)|
|10.||Shimada, Hitoshi: 4 articles (10/2015 - 02/2012)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2013 - "When 11C-PiB is used as a treatment endpoint in intervention studies for Alzheimer's disease (AD), a concern is whether the clearance of the tracer changes from one scan to the next, increasing within subject variability in the PET signal. "
03/01/2014 - "[(11)C]PIB has been used in PET studies to assess Aβ deposition in brain of patients with Alzheimer's disease (AD). "
02/01/2014 - "The aim of this study was to evaluate the longitudinal changes in [(11)C]PIB uptake in mild cognitive impairment (MCI) and Alzheimer's disease (AD) over a long-term follow-up. "
11/14/2006 - "PET studies with N-methyl-[(11)C]2-(4':-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) have revealed an increased tracer uptake in several brain regions in Alzheimer disease (AD). "
10/01/2015 - "11C-PiB PET imaging was considered to be the diagnostic reference standard, with a threshold standardized uptake value ratio of 1.5 being indicative of Alzheimer disease pathology. "
01/01/2015 - "Twenty-three subjects, 15 cognitively normal (NL) and 8 with a clinical diagnosis of Alzheimer's Dementia (AD), underwent [(11)C]PiB and [(18)F]flutemetamol PET scans within 28 days of study enrollment. "
02/01/2009 - "White matter kinetics were also characterized in vivo through 11C-PiB PET studies in 27 HCs and 34 patients with dementia. "
12/01/2015 - "(11) C-PiB PET may be of value in making the diagnosis of dementia and MCI in cases with high diagnostic uncertainty."
12/01/2015 - "Among 20 patients with possible AD dementia (PosAD), 17 were NI-positive, and six who were both NI- and (11) C-PiB-positive were categorized as having 'PosAD with evidence of the AD pathophysiological process'. "
12/01/2015 - "Among 40 patients with probable AD dementia (ProAD), 37 were NI-positive, 29 were (11) C-PiB-positive, and 27 who were both NI- and (11) C-PiB-positive were categorized as having 'ProAD dementia with a high level of evidence of the AD pathophysiological process'. "
03/01/2014 - "The possibility to visualize other types of amyloid deposits with [(11)C]PIB would be of potential clinical importance in early diagnosis and for following therapeutic effects. "
02/01/2013 - "In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET."
05/01/2012 - "The successful introduction of [(11)C]PIB as a PET tracer for the amyloid plaques less than 10 years ago started an intensive research, and numerous new compounds for use in molecular imaging of the amyloid plaques have been developed. "
09/01/2011 - "[(11)C]PIB is still the standard PET compound for Alzheimer imaging targeting beta-amyloid plaques. "
07/01/2011 - "The histologic and biochemical specificity of PiB binding across different regions of the AD brain was demonstrated by showing a direct correlation between Aβ-containing amyloid plaques and in vivo [(11)C]PiB retention measured by PET imaging. "
12/01/2011 - "Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals."
10/13/2009 - "High cortical [(11)C]PIB uptake may predict ongoing brain atrophy in cognitively normal individuals."
03/22/2011 - "Hippocampal atrophy and amyloid deposition seem to dissociate during the evolution of MCI, the atrophy increasing clearly and [(11)C] PiB retention changing modestly when conversion to AD occurs. "
12/01/2009 - "The in vivo measure of cerebral amyloidosis known as [(11)C]PiB is associated with cross-sectional regionally specific brain atrophy and longitudinal cognitive decline in multiple cognitive domains that occur before the clinical diagnosis of Alzheimer disease. "
07/01/2006 - "Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study."
|5.||Frontotemporal Lobar Degeneration (Semantic Dementia)
|1.||Amyloid (Amyloid Fibrils)
|2.||2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)
|3.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|4.||2- (1- (6- ((2- fluoroethyl)(methyl)amino)- 2- naphthyl)ethylidene)malononitrile
|7.||Biological Markers (Surrogate Marker)